ANI Pharmaceuticals Overview
- Founded
-
1996
- Status
-
Public
- Employees
-
601
- Stock Symbol
-
ANIP
- Investments
-
25
- Share Price
-
$35.84
- (As of Thursday Closing)
ANI Pharmaceuticals General Information
Description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Other Healthcare Services
Stock Exchange
NAS
Primary Office
- 210 Main Street West
- Baudette, MN 56623
- United States
+1 (218) 000-0000
ANI Pharmaceuticals Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $35.84 | $35.87 | $22.31 - $60.23 | $625M | 17.4M | 97.6K | -$4.30 |
ANI Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 746,487 | 958,187 | 528,619 | 871,921 |
| Revenue | 251,322 | 216,136 | 208,475 | 206,547 |
| EBITDA | (8,718) | 3,164 | 28,190 | 60,735 |
| Net Income | (63,636) | (42,603) | (22,548) | 6,094 |
| Total Assets | 751,334 | 771,598 | 461,190 | 456,789 |
| Total Debt | 286,945 | 287,370 | 185,686 | 185,749 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ANI Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ANI Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid
Pharmaceuticals
Baudette, MN
601
As of 2021
00000
000000000
00000
0000 0
do consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
000000000000000
Haifa Bay, Israel
0000
As of 0000
0000
0.000
0000-00-00
00000000000
000000
lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magn
000000000000000
Trevose, PA
000
As of 0000
000000000
Add Comparison
ANI Pharmaceuticals Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Taro Pharmaceutical Industries | Corporate Backed or Acquired | Haifa Bay, Israel | 0000 | 0000 | 00000000000 | |
| 0000000 0000000 | Corporation | Trevose, PA | 000 | 000000000 | ||
| 000000000000000 00 | Corporation | Lagos, Nigeria | 00 | |||
| 000000 00000000000 | Formerly PE-Backed | Bridgewater, NJ | 0000 | 00.000 | 000000 - 000 | 00.000 |
| 000000000000 | Corporation | Staines-Upon-Thames, United Kingdom | 0000 | 00.00 | 0000000000. |
ANI Pharmaceuticals Patents
ANI Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20120046264-A1 | Commercial scale production methods for transdermal hormone formulations | Abandoned | 17-Aug-2010 | 0000000000 | |
| US-20170232002-A1 | Commercial scale production methods for transdermal hormone formulations | Abandoned | 17-Aug-2010 | 0000000000 | |
| US-20120022033-A1 | Methods for decreasing cardiovascular risk in postmenopausal women | Abandoned | 23-Jul-2010 | 0000000000 | |
| US-20170128462-A1 | Methods for treating female sexual dysfunction while decreasing cardiovascular risk | Abandoned | 02-Jul-2010 | 0000000000 | |
| US-20120004204-A1 | Methods for treating sexual dysfunction while decreasing cardiovascular risk | Abandoned | 02-Jul-2010 | A61K31/568 |
ANI Pharmaceuticals Executive Team (17)
ANI Pharmaceuticals Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 0000 | ANI Pharmaceuticals | Board Member | 000 0000 |
| 00000 0000 00 | Self | Board Member | 000 0000 |
| 000000 00000 | ANI Pharmaceuticals | Board Member | 000 0000 |
| 000000000 000000000 | ANI Pharmaceuticals | Chief Operating Officer, Operations & Board Member | 000 0000 |
| 000000 0000000 | ANI Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
ANI Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ANI Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ANI Pharmaceuticals Investments & Acquisitions (25)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 28-Jun-2022 | 000000000 | Buildings and Property | 000000 00 | |
| 00000000 0000 | 19-Nov-2021 | 0000000000 | 00000 | Pharmaceuticals | 000000 00 |
| 000000 (0 000 | 06-Apr-2021 | 000000000 | Buildings and Property | 000000 00 | |
| 000 000000000 | 01-Jul-2020 | 000000000 | 000 | Buildings and Property | |
| Amerigen Pharmaceuticals | 09-Jan-2020 | Merger/Acquisition | 000.00 | Pharmaceuticals | 000000 00 |
ANI Pharmaceuticals Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000 000000 | Pharmaceuticals | East Windsor, NJ | 0000 |